金钗石斛为我国传统中药，具有益胃生津、滋阴清热等功效，其质量标准的建立一直是热点研究问题。金钗石斛主要包含生物碱类、菲类、联苄类、倍半萜类、多糖等多种化合物，主要具有改善糖脂代谢、保护神经系统、调节免疫反应、抗肿瘤等多种作用。在金钗石斛化学成分及药理研究基础上，基于中药质量标志物（Q-Marker）的概念，分析金钗石斛植物亲缘关系、生长年限、化学成分可测性、不同炮制方法、传统功效及网络药理学预测等，对金钗石斛的Q-Marker进行预测分析。选取化学成分可测定、功效相关的、成分含量较高的药效活性成分，石斛碱、毛兰素、石斛酚、moscatin可作为金钗石斛的Q-Marker。探讨可表征金钗石斛质量成分指标与药理作用及临床应用的内在关联性，为完善其质量标准提供依据。

Dendrobium nobile is a traditional Chinese herbal medicine, which has the effects of nourishing the stomach, nourishing yin and clearing heat, and the establishment of its quality standards has always been a hot research issue. In this paper, the research status of the pharmacodynamic relationship of D. nobile is reviewed from the aspects of chemical composition and pharmacological effects, which mainly contain alkaloids, phenanthrene, bibenzyls, sesquiterpenoids, polysaccharides and other compounds, which mainly have various effects such as improving glucose and lipid metabolism, protecting the nervous system, regulating immune response, and anti-tumor. On the basis of the research on the chemical composition and pharmacology of D. nobile and based on the concept of quality marker (Q-Marker) in traditional Chinese medicine, the plant kinship, growth years, chemical composition measurability, different processing methods, traditional efficacy and network pharmacological prediction of D. nobile were analyzed, and the Q-Marker of D. nobile was predicted and analyzed. The pharmacodynamic active ingredients with measurable chemical composition, related efficacy and high component content were selected, and it was preliminarily suggested that dendrobine, mullanin, dendrobol and moscatin should be used as quality markers of D. nobile. To explore the internal correlation between the quality component indexes and pharmacological effects and clinical application of D. nobile hairpin, so as to provide a basis for improving its quality standards.

R285

贵州省高等学校中药（民族药）药性与效应研究重点实验室资助项目（黔教技［2023］018号）;贵州中医药大学国家与省级科技创新人才团队培育项目（贵中医TD合字〔2023〕003号）;贵州省李辉武中药炮制技术传承基地建设项目（黔中医药函〔2024〕22号）;全国老药工王建科传承工作室（黔中医药函〔2024〕42号）